Abstract: Thrombolytic revascularization therapy still remains an important method in the treatment of ST-segment elevation myocardial infarction (STEMI). Recent clinical studies confirmed the status of thrombolytic therapy in 3 clinical situations:estimated long delay(>2 hours) in primary percutaneous coronary intervention (PCI), pharmco-invasive thrombolytic therapy with estimated PCI delay(1 hour), a large thrombus treated with intra-coronary use of low dose thrombolytic therapy during primary PCI. Above 3 conditions should be fully considered during clinical application.